Certain medications, though effective for their intended purposes, can cause significant cardiac side effects. Monitoring is essential to mitigate risks and ensure patient safety. Examples include:
Chemotherapy Agents: Drugs like doxorubicin and trastuzumab are known to cause cardiotoxicity, leading to heart failure or arrhythmias (NCI, 2025).
Antipsychotics: Medications such as haloperidol and olanzapine can prolong the QT interval, increasing the risk of life-threatening arrhythmias (APA, 2023).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Long-term use of NSAIDs like ibuprofen is linked to an elevated risk of heart attack or stroke (AHA, 2024).
Stimulants: Drugs prescribed for ADHD, such as amphetamines, can raise blood pressure and heart rate, posing risks for patients with underlying cardiac conditions (FDA, 2024).
How DigiBeat Helps
DigiBeat offers a game-changing solution by enabling monitoring of cardiac health. Its advanced machine learning can detect subtle changes in heart sounds and rhythms, allowing for early intervention. For patients on high-risk medications, DigiBeat provides:
Monitoring: Tracking heart function over time to identify early signs of cardiotoxicity.
Remote Access: Allowing healthcare providers to review data and make timely adjustments to treatment plans.
Personalized Insights: Leveraging machine learning to deliver patient-specific recommendations and alerts.
By integrating DigiBeat into the care regimen, healthcare providers can proactively manage the risks associated with these medications, improving outcomes and quality of life for patients.
Citations
National Cancer Institute (NCI). (2025). Cardiotoxicity of Chemotherapy Agents. Retrieved from cancer.gov.
American Psychiatric Association (APA). (2023). Cardiac Risks Associated with Antipsychotics. Psychiatry Journal.
Food and Drug Administration (FDA). (2024). Stimulants and Cardiac Risks. Retrieved from fda.gov.